ct26 cell lines  (ATCC)

Journal: Journal of Nanobiotechnology

Article Title: A metal-organic nanoframework for efficient colorectal cancer immunotherapy by the cGAS-STING pathway activation and immune checkpoint blockade

doi: 10.1186/s12951-024-02836-3

Figure Lengend Snippet: CS/NPs uptake and cytotoxicity. A , B Representative flow cytometry images depicting CT26 and RKO cell uptake following incubation with CS/NPs at different points in the experiment. C , D Flow cytometry images of uptake by CT26 and RKO cells after different treatments. E , F Viability of CT26 and RKO cells treated with different samples ( n = 3). G – J Assessment of colony formation and quantitative metrics in CT26 and RKO cell. K – N Fluorescence imaging and quantitative analysis of EdU labeling experiments in CT26 and RKO cells following various treatments. O – R Apoptosis in CT26 and RKO cells treated with different samples ( n = 3). *** p < 0.001

Article Snippet: The mouse-derived CRC cell line CT26 and the human-derived CRC cell line RKO was conducted in RPMI 1640 medium (Gibco) by adding 1% penicillin-streptomycin and 10% FBS.

Techniques: Flow Cytometry, Incubation, Fluorescence, Imaging, Labeling

Journal: Journal of Nanobiotechnology

Article Title: A metal-organic nanoframework for efficient colorectal cancer immunotherapy by the cGAS-STING pathway activation and immune checkpoint blockade

doi: 10.1186/s12951-024-02836-3

Figure Lengend Snippet: CS/NPs biodistribution and anti-tumor efficacy in-vivo. A Quantitative analysis and real-time fluorescence imaging in-vivo of the CT26-Luc subcutaneous tumor model. B Fluorescence intensity analysis ex vivo in primary organs and tumor tissues. C Schematic illustration of in-vivo drug treatment in the unilateral mouse tumor model. D Body weight modifications across six mouse cohorts under different drug treatments ( n = 5). E Comparison of tumor volume curves ( n = 5). F – K Tumor volume change curves ( n = 5). L Corresponding tumor photographs, scale bar: 1 cm ( n = 5). M Average tumor weight and inhibition rate ( n = 5). N Images depicting tumor tissues collected from various groups subjected to Ki67 immunohistochemistry, and H&E staining. With a Scale bar: 50 μm. *** p < 0.001

Article Snippet: The mouse-derived CRC cell line CT26 and the human-derived CRC cell line RKO was conducted in RPMI 1640 medium (Gibco) by adding 1% penicillin-streptomycin and 10% FBS.

Techniques: In Vivo, Fluorescence, Imaging, Ex Vivo, Comparison, Inhibition, Immunohistochemistry, Staining

Journal: Journal of Nanobiotechnology

Article Title: A metal-organic nanoframework for efficient colorectal cancer immunotherapy by the cGAS-STING pathway activation and immune checkpoint blockade

doi: 10.1186/s12951-024-02836-3

Figure Lengend Snippet: CS/NPs induce cGAS-STING-mediated enhancement of distant tumor immunity. A Schematic representation of treatment for a bilateral subcutaneous Luc-CT26 tumor bearing model. B Corresponding primary tumor photographs, scale bar: 1 cm. C Comparison of primary tumor volume curves for the six groups during different drug treatments ( n = 5). D Average tumor weights and inhibition rates ( n = 5). E Corresponding distant tumor photographs, scale bar: 1 cm ( n = 5). F Tumor volume curves ( n = 5). G Average tumor weights and inhibition rates ( n = 5). H H&E and immunohistochemical Ki67 staining In primary tumor tissue for each group, scale bar: 50 μm. I H&E and immunohistochemical Ki67 staining in distant tumor tissue, scale bar: 50 μm. *** p < 0.001

Article Snippet: The mouse-derived CRC cell line CT26 and the human-derived CRC cell line RKO was conducted in RPMI 1640 medium (Gibco) by adding 1% penicillin-streptomycin and 10% FBS.

Techniques: Comparison, Inhibition, Immunohistochemical staining, Staining

Journal: Scientific Reports

Article Title: Non-clinical evaluation of pmIL12 gene therapy for approval of the phase I clinical study

doi: 10.1038/s41598-024-73314-x

Figure Lengend Snippet: Pharmacokinetic properties of the pmIL12 GET. The percentage of organs/tissues positive for the pmIL12 plasmid was confirmed in various organs at different time points: day 2 ( A ), day 8 ( B ), day 14 ( C ), and long-term ( D ) after GET with three different doses of pmIL12 into CT26 tumors. ( E ) The number of copies of the pmIL12 plasmid in the skin above and around the tumor after pmIL12 GET into CT26 tumors. Green * P < 0.05 versus day 2 0.5 mg/ml, red * P < 0.05 vs day 2 1 mg/ml, ns—not statistically significant.

Article Snippet: After quarantine, the mice were shaved with clippers on one flank, and tumors were induced via the subcutaneous injection of 0.3 × 10 6 CT26 cells (CRL-2638™, ATCC, Manassas, VA, USA) in 100 µL of saline with a syringe with a 27G needle.

Techniques: Plasmid Preparation

Journal: Scientific Reports

Article Title: Non-clinical evaluation of pmIL12 gene therapy for approval of the phase I clinical study

doi: 10.1038/s41598-024-73314-x

Figure Lengend Snippet: Weights of the mice and IgG and IgM antibody levels as measures of the systemic toxicity of pmIL12 GET. Weight curves of BALB/c males ( A ) and females ( B ) with induced CT26 tumors that were treated with pmIL12 GET at three different doses: 0.5 mg/ml, 1 mg/ml, or 2 mg/ml. Control, untreated mice (Ctrl) that did not receive pmIL12 or electric pulses. Total serum levels of IgG ( C —males, D —females) and IgM ( E —males, F —females) antibodies after pmIL12 GET in CT26 tumors treated with three different doses of pmIL12: 0.5 mg/ml, 1 mg/ml, or 2 mg/ml. Control, untreated mice (Ctrl) that did not receive pmIL12 or electric pulses. Naïve mice (naïve) were tumor free and did not receive pmIL12 or GET. ns— P > 0.05 versus naïve.

Article Snippet: After quarantine, the mice were shaved with clippers on one flank, and tumors were induced via the subcutaneous injection of 0.3 × 10 6 CT26 cells (CRL-2638™, ATCC, Manassas, VA, USA) in 100 µL of saline with a syringe with a 27G needle.

Techniques: Control